Drug Details
General Information of the Drug (ID: DR7799) | ||||
---|---|---|---|---|
Name |
Sulfinosine
|
|||
Synonyms |
2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide; 2-Amino-9-beta-ribofuranosylpurine-6-sulfinamide; SCHEMBL6907463; 9H-Purine-6-sulfinamide, 2-amino-9-beta-D-ribofuranosyl-; DTXSID70924860; 2-amino-9-beta-d-ribofuranosylpurine-6-sulfinamide; 2-Amino-9-beta-D-ribofuranosyl-9H-purine-6-sulfinamide; 2-Imino-9-pentofuranosyl-3,9-dihydro-2H-purine-6-sulfinamide
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Lung cancer [ICD-11: 2C25] | Investigative | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C10H14N6O5S
|
|||
PubChem CID | ||||
Canonical SMILES |
C1=NC2=C(N1C3C(C(C(O3)CO)O)O)N=C(N=C2S(=O)N)N
|
|||
InChI |
1S/C10H14N6O5S/c11-10-14-7-4(8(15-10)22(12)20)13-2-16(7)9-6(19)5(18)3(1-17)21-9/h2-3,5-6,9,17-19H,1,12H2,(H2,11,14,15)/t3-,5-,6-,9-,22?/m1/s1
|
|||
InChIKey |
NIXVOFULDIFBLB-QVRNUERCSA-N
|
|||
CAS Number |
CAS 124508-99-2
|
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | GSTP1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | TOP2A | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in S and G2/M phase | ||||
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Sulfinosine and curcumin overcome MDR in non-small cell lung carcinoma cell line (NSCLC) by regulating the expression of MDR-related genes mdr1, gst-pi and topo Iialpha. |